Abstract
Introduction

66
The ability to accurately predict the predisposition to respond or actual response of T cells infiltration within the tumor niche or invasive margin, commonly referred to as the T cell-85 inflamed and non-T cell-inflamed tumor microenvironment (TME) phenotype, respectively (13).
86
The T cell-inflamed phenotype is characterized by pre-existing intra-tumoral or marginal Hence, an in-silico model that accurately predicts drug efficacy based on the molecular 103 constitution of patients' tumor would be a step in the right direction towards precision medicine.
104
Based on increasingly compelling evidence that chemosensitivity is strongly dependent on 105 alterations in the cancer proteogenomic landscape, this present study investigated the feasibility 106 of predicting drug response and now present an histology-independent model for predicting 107 response to pembrolizumab (anti-PD-1), ipilimumab (anti-CTLA-4), or nivolumab (anti-PD-1)
the active molecular components of that pathway (6 -9); the knowledge of which generally Unsupervised machine learning techniques used in this study.
210
For ICBT effect prediction, we used a data cluster of 5 variables, namely 4 proteome expression of the machine learning models, with all the instances being randomly assigned to one of 10 sets.
240
For each cross-validation, 1 set was used for testing and the other 9 used for machine training. At 241 the end of validation, the mean error across the 10 tests was estimated (23). Unsupervised 242 hierarchical clustering was performed using online free statistics and forecasting softwares.
243
Distances were computed based on correlation, the distance type was Euclidean, the clustering 244 method was group average unweighted pair-group, and scale type was standard deviation. were 2-sided and p-value < 0.05 was considered statistically significant. while conversely, high CTNNB1 expression was mostly associated with MPG ≤ 2 (Figure 2A) .
304
In addition, using the AFFY_HG_U133_PLUS_2, E-GEOD-28702 dataset for 83 CRC patients 305 subjected to FOLFOX therapy, we observed a positive correlation between enhanced CD3G,
306
CD8A or CD274 expression levels and response to therapy, while high CTNNB1 expression strongly correlated with lack of response ( Figure 2B ). Since the pathological complete response which is shown in Figure 3A . For preliminary tests, we assessed internally generated 336 immunohistochemistry data ( Figure 3B ) by using several known machines learning algorithms, In parallel experiments, we examined the feasibility of developing a patient-specific, evidence-
413
based mathematical prediction algorithm of ICBT response based on our selected gene-set. Thus,
414
based on accrued exploratory cohort data (n = 12), we determined that our control variable was 415 the malignancy itself, while our controllable variables (x) were CTNNB1, PD274, CD3G, CD8A
416
and CD3G/CD8A, and denoting them with x1, x2, x3, x4, x5, respectively, such that: We then sought to develop a mathematical formula f() that satisfies the equation:
, which translates into,
such that the predicted response to ICBT is a function or dependent on variation in CTNNB1,
422
CD274, CD3G and CD8A protein profile, as well as the immune score, CD3G/CD8A.
423
To generate the predictive mathematical model, we decided on the use of basic (constant, input 424 variable, addition, subtraction, multiplication, division), trigonometry (sine, cosine), and 425 exponential (exponential, natural logarithm, power) as the formula building blocks; set 426 significant level (α) was 0.05, and a 30% test set size used to detect curve over-fitting.
427
Using the Eur curve-fitting software, we finally derived and selected the mathematical predictive Table S1 ).
To confirm the relative impact of each decision variable (x), namely, CD8A, CD274, and Table   467 S2).
468
Finally, in a double-blind trial, as we remained blind to patients' clinicopathological 469 characteristics, we tested the functionality and clinical accuracy of the generated prediction 470 algorithm. As a demonstration of the predictive accuracy and clinical applicability of our model,
471
we now present 3 clinical cases validating our prediction model. 
